Study #lymphoma, #epigenetics, #protac, #immune @PMcancercentre🇨🇦 | Founder @UHNPostdocs | Delegate @OICRRisingStars | Alum @PeterMacCC🇦🇺
Toronto, Ontario
Joined May 2021
- Tweets442
- Following288
- Followers228
- Likes2.8K
Michael He, Ph.D., BPharm (Hons) retweeted
We are looking for a talented postdoctoral bioinformatician @TheDawsonLab to work with us on single cell multiomics incorporating lineage tracing and spatial technologies- we specifically want someone curious, fearless with a licence to innovate!! nature.com/naturecareers/job…
Michael He, Ph.D., BPharm (Hons) retweeted
UHN is proud to be ranked #1 on the list of Canada’s Top 40 Research Hospitals from @R_Infosource for the 14th year in a row!
Thanks to our incredible research community for their continued dedication to #HealthDiscovery, #care & #education!
🔗uhnresearch.ca/news/uhn-isca…
Michael He, Ph.D., BPharm (Hons) retweeted
Can we turn the activity of oncogenic kinases against cancer itself?
In my postdoc work @Stanford, new in @sciencemagazine, we show exactly that.
science.org/doi/10.1126/scie…
#ScienceResearch #InducedProximity @Stanford_ChEMH @StanfordCancer @snsf_ch @StanfordMed
I know I must read this masterpiece when I see @MAF_Dawson!
Very happy to see a comprehensive review on the hallmarks of cancer - an epigenetic perspective. Thank you to all the authors.
🥁Out today in the October issue of @CD_AACR: ⭐️The Epigenetic Hallmarks of Cancer⭐️ - by @ManelEsteller, @MAF_Dawson, @CKadoch, Feyruz Rassool, Peter Jones, and Steve Baylin doi.org/10.1158/2159-8290.CD…
Michael He, Ph.D., BPharm (Hons) retweeted
Transcriptional/epigenetic chemical inducers of proximity (TCIPs) are an innovative new class of therapeutics that are set to impact lymphoma and other malignancies. Here @RomanSarott, @saigourisankar describe a CDK9 "catch and release" MOA for a new TCIP.
science.org/doi/10.1126/scie…
Michael He, Ph.D., BPharm (Hons) retweeted
As #BloodCancerAwarenessMonth wraps up, we want to congratulate @PMResearch_UHN’s Dr. Robert Kridel @rkridel for publishing three new studies on #lymphoma.
Learn about his team’s dedication to advancing cancer research:
📽️youtu.be/XP0Tnwt2iHY
Excited to kick off the fight against #lymphoma with a first score! Honored to work with Dr. Kridel and a great team for these achievements. As Michael Jordan said, 'Talent wins games, but teamwork and intelligence wins championships.' Here’s to more victories in cancer research!
As #BloodCancerAwarenessMonth wraps up, we want to congratulate @PMResearch_UHN’s Dr. Robert Kridel @rkridel for publishing three new studies on #lymphoma.
Read about his team’s dedication to advancing cancer research using genetic analysis.
🔗uhnresearch.ca/news/cracking… @UHN
As Chair of the Program Committee for the 1st UHN Postdoc Symposium last year, I know how much effort goes into these events. Great job to the current team on the 2nd! Highly recommend all UHN postdocs join to get inspired and connect. Register now!
Michael He, Ph.D., BPharm (Hons) retweeted
In vivo CRISPR screen of Epigenetic regulators identity therapeutic targets that rely on tumor microenvironment - our recent work is out at Nature Genetics nature.com/articles/s41588-0…
Great teamwork @SoundTsao @DanielSchramek @decarvalho_lab @brooks_lab @kuraoncology and many others
How does mimicking a viral infection in cancer cells boost epigenetic therapy and anti-tumor immunity? 🧬
Check out our latest blog on targeting HDAC3 in lymphoma! 💡
👉 Read more communities.springernature.c…
#CancerResearch #Epigenetics #Lymphoma #HDAC3 #ViralMimicry #Oncology
Targeting epigenetic disruptions in cancer holds promise. Our latest paper in @LeukemiaJnl reveals a novel viral mimicry-interferon mechanism enhancing HDAC3 inhibition in GNAS knockout lymphoma. Proud to lead this challenging project with an amazing team!
nature.com/articles/s41375-0…
Michael He, Ph.D., BPharm (Hons) retweeted
👏👏 Super kudos to @pmcancercentre @rkridel for this outstanding translational work in follicular #lymphoma.
From 713 tumor tissue samples (eg, E4402, E2408 & GALLIUM), 5 genetic subtypes discovered and a/w clinicopath findings & pt outcomes.
👉👉 SEE: rdcu.be/dQmEk
Targeting epigenetic disruptions in cancer holds promise. Our latest paper in @LeukemiaJnl reveals a novel viral mimicry-interferon mechanism enhancing HDAC3 inhibition in GNAS knockout lymphoma. Proud to lead this challenging project with an amazing team!
nature.com/articles/s41375-0…
Thank you Dr. Patrizia Mondello @pattymondello for highlighting our work and the wonderful perspective! nature.com/articles/s41375-0…
A special thank you to my advisor @rkridel, mentor @hansenhe7, and all collaborators @YufengXiaoUF @WenxiXu @brooks_lab! Deeply grateful to Prof. Mark Dawson @MAF_Dawson, Prof. Steven Stacker, and @thePMCF @PMResearch_UHN @UHN_Research @uhntrainees @UHNPostdocs for their support!
Michael He, Ph.D., BPharm (Hons) retweeted
Our perspective on the synergistic activity of HDAC3i and GNAS silencing in CREBBP wild type B cell lymphoma #RobertKridel @themichaelhe #PrincessMargaretCancerCenter @MayoClinic nature.com/articles/s41375-0…
Michael He, Ph.D., BPharm (Hons) retweeted
Our HDAC8 degrader work is now online in JMC! Many thanks to the teams and PIs. Special thanks to colleagues @themichaelhe, Tom Lin& @RashmiKarki12. Stay tuned for more exciting discoveries!
Discovery of a Highly Potent and Selective HDAC8 Degrader: Advancing the Functional Understanding and Therapeutic Potential of HDAC8 | Journal of Medicinal Chemistry pubs.acs.org/doi/10.1021/acs…
